ScreenerHero

ALGS Aligos Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aligos.com
5.320USD-1.12%Mkt Cap: 33.22M $P/E: —

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap33.22M USD
Enterprise Value6.72M USD
Revenue (TTM)31.52M USD
Gross Profit-56.86M USD
Net Income (TTM)-24.19M USD
Revenue/Share3.03 USD
Last Price5.320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.03
PEG—
EV/EBITDA-0.09
EV/Revenue0.21
P/S1.07
P/B1.05
EPS (TTM)-7.41
EPS (Forward)-5.25
52W Range
3.98014% of range13.69
52W High13.69 USD
52W Low3.980 USD
Profitability
Gross Margin-180.40%
Oper. Margin-6.80%
EBITDA Margin-247.21%
Profit Margin-1106.72%
ROE-45.18%
ROA-27.33%
Growth
Revenue Growth2778.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-82.50M USD
CapEx (TTM)437.00K USD
FCF Margin-194.78%
FCF Yield-184.79%
Net Debt-26.88M USD
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity0.10
Current Ratio2.19
Quick Ratio2.05
Book Value/Sh5.11 USD
Cash/Share4.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 19, 2024
Analyst Consensus
Rating—
Target (Mean)52.38 USD
Upside (mean)+884.5%
Target Range20.00 USD – 175.00 USD
20.00+884.5% to mean175.00
# Analysts8
Ownership
Shares Out.5.44M
Float3.68M
Insiders10.64%
Institutions42.16%
Short Interest
Short Ratio11.9d
Short % Float13.15%
Short % Out.11.17%
Shares Short697.68K
Short (prev mo.)568.06K
Technical
SMA 505.801 (-8.3%)
SMA 2006.673 (-20.3%)
Beta2.36
S&P 52W Chg16.45%
Avg Vol (30d)46.88K
Avg Vol (10d)44.76K
Technical Indicators
RSI (14)42.5
MACD-0.1212
MACD Signal-0.1128
MACD Hist.-0.0084
BB Upper5.843 USD
BB Middle5.440 USD
BB Lower5.037 USD
BB Width14.82%
ATR (14)0.4160 USD
Vol Ratio (20d)0.45x